Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of IPdR in Combination With Capecitabine and Radiotherapy in Rectal Cancer

NCT04406857 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04406857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04406857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of IPdR in Combination With Capecitabine and Radiotherapy in Rectal Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Terminated
Start date
March 17, 2021
Completion date
January 18, 2023
Enrollment
1 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced rectal carcinoma, rectal adenocarcinoma, stage ii rectal cancer ajcc v8, stage iii rectal cancer ajcc v8